KALV Stock: 8 Things to Know About KalVista Pharmaceuticals as Shares Skyrocket TodayInvestorPlace • 02/09/21
Investors Cheer Positive Data From KalVista's KVD900 Mid-Stage Hereditary Angioedema TrialBenzinga • 02/09/21
Kalvista Rockets To 5-Year High On 'Overwhelmingly Positive' Test ResultsInvestors Business Daily • 02/09/21
KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE AttacksBusiness Wire • 02/09/21
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences TeamBusiness Wire • 01/26/21
Are Options Traders Betting on a Big Move in KalVista Pharmaceuticals (KALV) Stock?Zacks Investment Research • 01/11/21
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema FranchiseBusiness Wire • 10/15/20
KalVista Pharmaceuticals, Inc. (KALV) Shares March Higher, Can It Continue?Zacks Investment Research • 12/06/19